GentiBio, Inc., a Seattle, WA-based biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, closed a $20m seed funding.
The round was led by OrbiMed, Novartis Venture Fund and RA Capital Management, L.P.
Led by Adel Nada, M.D., Chief Executive Officer, GentiBio is an early stage biotherapeutics company focused on leveraging Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.
The company has also entered into exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRI), and MIGAL Galilee Research Institute (MIGAL) to advance its unique immune tolerance platform.
Under the terms of the licensing agreements, Seattle Children’s, BRI and MIGAL will exclusively license unique technologies to GentiBio that overcome many of the current limitations of Tregs therapeutics, including rarity and plasticity of endogenous Tregs populations.
Additionally, GentiBio’s platform will enable the scaled production of EngTregs cell therapy products that are antigen specific and tunable.
The platform may also have the potential to accelerate the development of new therapeutics to treat and cure a variety of diseases, including autoimmune diseases.